Friday to Sunday, April 24 to April 26, 2026

Topics and schedule are subject to change. Times indicated are eastern time.

Friday, April 24, 2026 | Keynote

6:30 PM – 7:00 PM — Registration and Welcome Reception

7:00 PM – 9:00 PM — Keynote Session: Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Antibody-Drug Conjugates and Other Novel Strategies in the Management of DLBCL

• Extended follow-up from the Phase III POLARIX trial of polatuzumab vedotin/R-CHP (rituximab/cyclophosphamide/doxorubicin/prednisone) for previously untreated DLBCL
• Ongoing Phase III ESCALADE trial of acalabrutinib and R-CHOP for younger patients with untreated non-germinal center B-cell type DLBCL
• Key findings from the Phase III POLARGO study of polatuzumab vedotin with rituximab/gemcitabine/oxaliplatin for relapsed/refractory (R/R) DLBCL
• Extended follow-up from the Phase II LOTIS-2 study of loncastuximab tesirine for R/R DLBCL
• Preliminary data, such as from the LOTIS-7 trial and the LOTIS-5 safety run-in, with loncastuximab tesirine in combination with other therapies
• Outcomes with golcadomide-containing regimens for newly diagnosed and R/R DLBCL; ongoing Phase III GOLSEEK-1 trial

Current and Future Role of Monoclonal and Bispecific Antibodies in the Management of DLBCL

• Extended follow-up with tafasitamab/lenalidomide for patients with R/R DLBCL
• Emerging positive findings from the Phase III frontMIND trial of tafasitamab with lenalidomide and R-CHOP as first-line treatment
• Available and emerging outcomes from pivotal studies of glofitamab and epcoritamab monotherapy in R/R DLBCL
• Phase III findings with bispecific antibodies in combination with other anticancer therapies and/or in earlier settings for DLBCL, including results from the STARGLO and SUNMO studies
• Antitumor activity with and ongoing evaluation of surovatamig for patients with R/R DLBCL

Chimeric Antigen Receptor (CAR) T-Cell Therapy for DLBCL

• Long-term data with axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tis-cel) and lisocabtagene maraleucel (liso-cel) for multiregimen-relapsed DLBCL
• Major findings from Phase III studies of CAR T-cell therapy as second-line treatment
• Preliminary results with and ongoing assessment of CAR T-cell therapy in the up-front setting for high-risk disease
• Early results with and ongoing investigation of other CAR T-cell platforms for DLBCL, such as rapcabtagene autoleucel

Integrating Bispecific Antibodies into the Management of FL

• Activity and tolerability documented with mosunetuzumab and epcoritamab monotherapy for patients with R/R FL
• Outcomes from the Phase III EPCORE FL-1 study of epcoritamab and lenalidomide/rituximab (R²) for R/R FL
• Available research findings with other bispecific antibody-based combinations for FL, including results from the US extension cohort of the Phase III Celestimo trial
• Ongoing Phase III trials of bispecific antibodies for FL, including as first-line treatment and/or in combination with other anticancer therapies
• Early results with surovatamig for patients with R/R FL; ongoing evaluation in the Phase III SOUNDTRACK-F1 study

CAR T-Cell Therapy for FL

• Extended follow-up with axi-cel, tis-cel and liso-cel for multiregimen-relapsed FL
• Outcomes from the subgroup of patients with high-risk FL receiving second-line therapy in the Phase II TRANSCEND FL study of liso-cel for R/R FL
• Ongoing and planned trials of CAR T-cell therapy for R/R FL, such as ZUMA-22, LEDA and TRANSFORM FL
• Preliminary data and ongoing clinical research with next-generation CAR T-cell platforms for R/R FL

Other Approved and Emerging Novel Therapies for FL

• Key findings from the Phase III inMIND trial of tafasitamab and R² for R/R FL
• Available data with loncastuximab and rituximab for R/R FL; NCCN guideline inclusion as a third- or later-line treatment option
• Published data with zanubrutinib in combination with obinutuzumab for patients with R/R FL
• Emerging safety data from the Phase Ib/III SYMPHONY-1 trial leading to the recent withdrawal of tazemetostat
• Early findings with golcadomide and rituximab for heavily pretreated FL; ongoing evaluation in the GOLSEEK-4 and GOLSEEK-2 trials

Saturday, April 25, 2026

7:00 AM – 8:00 AM — Registration and Breakfast

8:00 AM – 8:50 AM — Module 1: Chronic Lymphocytic Leukemia

Management of Newly Diagnosed Chronic Lymphocytic Leukemia (CLL)

• Clinical, biological (eg, IGHV mutation, del[17p], TP53 mutation) and practical factors influencing front-line therapeutic selection for patients with CLL requiring treatment
• Long-term findings from Phase III studies assessing ibrutinib-, acalabrutinib- and zanubrutinib-based therapy for treatment-naïve and relapsed/refractory (R/R) CLL; application in current up-front decision-making
• Pharmacologic similarities and differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors
• Recently published findings from the Phase III BRUIN CLL-314 study of pirtobrutinib versus ibrutinib for patients with treatment-naïve or previously treated, BTK inhibitor-naïve CLL
• Recently documented efficacy advantage with pirtobrutinib versus bendamustine/rituximab for patients with treatment-naïve CLL without del(17p) in the Phase III BRUIN CLL-313 trial
• Potential clinical role of pirtobrutinib in treatment for newly diagnosed CLL
• Key efficacy and safety data with venetoclax-based up-front treatment for CLL; potential benefits and identification of appropriate candidates for time-limited therapy
• Spectrum, frequency and severity of adverse events with BTK inhibitors and Bcl-2 inhibitors; optimal monitoring and management protocols

Novel Agents and Combination Strategies

• Mechanistic rationale for combining BTK inhibitors and venetoclax with and without anti-CD20 antibodies for CLL
• Published efficacy and safety findings from the Phase III AMPLIFY trial of fixed-duration acalabrutinib in combination with venetoclax with or without obinutuzumab for previously untreated CLL
• Recent FDA approval of fixed-duration acalabrutinib and venetoclax for patients with treatment-naïve CLL
• Recently published efficacy and safety findings from the Phase III CLL17 trial comparing continuous BTK inhibition to time-limited venetoclax-based doublets
• Early data with and ongoing studies of zanubrutinib in combination with Bcl-2 inhibitors, such as venetoclax and sonrotoclax, with or without an anti-CD20 antibody for previously untreated and R/R CLL
• Long-term efficacy and safety findings with pirtobrutinib for patients with BTK inhibitor-pretreated CLL; current clinical role and related FDA approval
• Published safety and efficacy findings from the Phase III ALPINE trial of zanubrutinib versus ibrutinib for R/R CLL
• Published efficacy and safety findings with lisocabtagene maraleucel (liso-cel) for R/R CLL from the Phase I/II TRANSCEND CLL 004 trial
• FDA approval of liso-cel for CLL previously treated with a BTK inhibitor and a Bcl-2 inhibitor; optimal selection of patients
• Mechanistic similarities and differences between BTK degraders and BTK inhibitors; preliminary data with and ongoing evaluation of BTK degraders, such as BGB-16673, for patients with heavily pretreated CLL
• Other promising agents and strategies under investigation for CLL

8:50 AM – 9:40 AM — Module 2: Pancreatic Cancer

Optimal Incorporation of Chemotherapy into the Management of Advanced Pancreatic Cancer

• Clinical and biological factors affecting the choice of up-front and later-line therapy for patients with metastatic pancreatic adenocarcinoma (PAD)
• Historical data establishing the efficacy and safety of FOLFIRINOX and gemcitabine/nab paclitaxel for patients with previously untreated advanced PAD
• Key findings, including recently updated overall survival data, from the Phase III NAPOLI 3 trial comparing frontline NALIRIFOX to gemcitabine/nab paclitaxel for advanced PAD
• Current clinical role of and selection of optimal candidates for up-front NALIRIFOX therapy
• Comparative tolerability/toxicity profile of NALIRIFOX versus FOLFIRINOX and gemcitabine/nab paclitaxel; recommended mitigation, monitoring and management approaches for treatment-related adverse events
• Effect of dose adjustment on the efficacy of first-line NALIRIFOX; implications for the feasibility of a tolerability-guided dosing strategy
• Long-term findings with nanoliposomal irinotecan (nal-IRI) in combination with 5-FU/leucovorin for patients with metastatic PAD experiencing disease progression on gemcitabine-based therapy; clinical role of nal-IRI in the relapsed/refractory setting

Other Available and Emerging Novel Approaches for Pancreatic Cancer

• Incidence and clinical relevance of NRG1 gene fusions in pancreatic cancer; appropriate method and timing of assessment
• Mechanism of action of zenocutuzumab; key efficacy and safety data among patients with advanced PAD from the pivotal Phase I/II eNRGy study evaluating zenocutuzumab for solid tumors harboring NRG1 fusions
• FDA approval and optimal incorporation of zenocutuzumab into therapy for previously treated advanced PAD harboring NRG1 gene fusions
• Spectrum of RAS mutations in PAD; mechanistic similarities and differences among daraxonrasib and the commercially available KRAS G12C inhibitors sotorasib and adagrasib
• Early efficacy and safety results with daraxonrasib as monotherapy and in combination with gemcitabine/nab paclitaxel for patients with advanced pancreatic cancer and RAS mutations
• FDA breakthrough therapy designation of daraxonrasib as monotherapy for metastatic pancreatic ductal adenocarcinoma with KRAS G12X mutations
• Ongoing Phase III trials, such as RASolute 302, RASolute 303 and RASolute 304, of daraxonrasib alone or in combination with chemotherapy for patients with PAD
• Preliminary safety and efficacy data with zoldonrasib among patients with KRAS G12D-mutated advanced PAD; future development plans
• Other promising novel agents and strategies for PAD

9:40 AM – 10:00 AM — Morning Break

10:00 AM – 10:50 AM — Module 3: Ovarian Cancer

PARP Inhibitors and Strategies Targeting Folate Receptor Alpha (FRα) in Advanced Ovarian Cancer (OC)

• Optimal approaches to biomarker testing for patients with newly diagnosed advanced OC; significance of somatic and germline BRCA mutations and homologous recombination deficiency status for treatment decision-making
• Long-term findings, including overall survival (OS) outcomes, from Phase III studies of maintenance therapy with olaparib, olaparib/bevacizumab and niraparib for patients with newly diagnosed OC
• Clinical, biological and practical factors in the selection of up-front olaparib, olaparib/bevacizumab or niraparib for maintenance therapy
• Current clinical utility, if any, of PARP inhibitors for patients with relapsed/refractory OC, including those who have experienced disease progression on or after prior PARP inhibitor therapy
• Incidence and clinical relevance of FRα expression in OC; optimal approaches to and timing of FRα testing
• Long-term data, including OS findings, with mirvetuximab soravtansine for patients with FRα-positive, platinum-resistant OC
• FDA approval of mirvetuximab soravtansine for FRα-positive, platinum-resistant OC; implications for current management
• Early findings with mirvetuximab soravtansine for FRα-positive, platinum-sensitive advanced OC; ongoing Phase III evaluation in the GLORIOSA trial and potential utility in this setting
• Mechanistic similarities and differences between investigational FRα-targeted antibody-drug conjugates, such as rinatabart sesutecan or torvutatug samrotecan, and mirvetuximab soravtansine
• Early data with and ongoing Phase III evaluation of investigational FRα-targeted antibody-drug conjugates for FRα-expressing, platinum-resistant OC

Other Novel Agents and Strategies for the Treatment of Advanced OC

• Mechanism of antitumor activity of the selective glucocorticoid receptor modulator relacorilant and rationale for its evaluation in advanced OC
• Key findings, including OS data, from the Phase III ROSELLA study evaluating relacorilant with nab paclitaxel versus nab paclitaxel alone for patients with platinum-resistant advanced OC
• Recent FDA approval of relacorilant in combination with nab paclitaxel for platinum-resistant OC; clinical applications
• Available data, including OS outcomes, from the Phase III KEYNOTE-B96 study evaluating the addition of pembrolizumab to chemotherapy, with or without bevacizumab, for patients with platinum-resistant recurrent OC
• Recent FDA approval and clinical applications of pembrolizumab in combination with paclitaxel, with or without bevacizumab, for patients with PD-L1-positive, platinum-resistant recurrent OC
• Frequency of HER2 expression in advanced OC; outcomes achieved with trastuzumab deruxtecan (T-DXd) for patients with advanced OC in the DESTINY-PanTumor02 trial
• Ongoing Phase III DESTINY-Ovarian01 trial seeking to further define the role of T-DXd in therapy for advanced OC
• Tumor-agnostic FDA approval of T-DXd and the implications for OC management
• Biological rationale for targeting CDH6 in OC; mechanism of antitumor activity of the novel CDH6-directed antibody-drug conjugate raludotatug deruxtecan (R-DXd)
• Available research findings with R-DXd for platinum-resistant advanced OC, including those from the Phase II dose optimization part of the ongoing Phase II/III REJOICE-Ovarian01 study
• FDA breakthrough therapy designation of R-DXd for patients with platinum-resistant epithelial OC expressing CDH6 who have received prior treatment with bevacizumab; potential clinical role
• Other promising novel agents and strategies with R-DXd for platinum-resistant advanced OC, such as TROP2-targeted antibody-drug conjugates

10:50 AM – 11:40 AM — Module 4: Relapsed/Refractory Multiple Myeloma

Integrating Chimeric Antigen Receptor (CAR) T-Cell Therapy and Bispecific Antibodies into the Management of Relapsed/Refractory (R/R) Multiple Myeloma (MM)

• Key clinical and biological factors in the selection and sequencing of therapy for patients with R/R MM
• Research database documenting the effectiveness of idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) in patients with pretreated MM
• Identification of appropriate candidates for ide-cel and cilta-cel; optimal sequencing of CAR T-cell therapy in view of other evidence-based approaches
• Early data with the GPRC5D-targeted CAR T-cell therapy arlocabtagene autoleucel for R/R MM; FDA regenerative medicine advanced therapy designation and ongoing evaluation
• Available efficacy and safety findings leading to the FDA approvals of the BCMA-directed bispecific antibodies teclistamab, elranatamab and linvoseltamab for R/R MM; optimal incorporation into management algorithms
• Published data from the Phase III MajesTEC-3 trial evaluating teclistamab/daratumumab versus investigator’s choice of daratumumab/dexamethasone with either pomalidomide or bortezomib for patients with R/R MM; related FDA approval and clinical applications
• Key efficacy and safety data with the non-BCMA-targeted bispecific antibody talquetamab for heavily pretreated disease; optimal selection of candidates and sequencing of this agent
• Preliminary data and ongoing clinical research with other novel CAR T-cell platforms, bispecific antibodies and trispecific antibodies for R/R MM
• Spectrum, incidence and severity of acute and long-term toxicities with CAR T-cell therapy and bispecific antibodies in patients with MM; optimal mitigation and management protocols

Antibody-Drug Conjugates (ADCs) and Other Emerging Therapies for R/R MM

• Mechanism of action and structural components of the BCMA-directed ADC belantamab mafodotin
• Key efficacy and safety data from the Phase III DREAMM-7 and DREAMM-8 trials evaluating belantamab mafodotin in combination with bortezomib/dexamethasone and pomalidomide/dexamethasone, respectively, for patients who have received 1 or more prior lines of therapy; overall survival findings from DREAMM-7
• FDA approval and current role of belantamab mafodotin-based combination strategies in the management of R/R MM
• Spectrum, frequency and severity of toxicities, including ocular adverse events, reported with belantamab mafodotin; appropriate mitigation, monitoring and management techniques
• Mechanism of action of cereblon E3 ligase modulators (CELMoDs); similarities and differences among iberdomide, mezigdomide and standard immunomodulatory drugs
• Available data documenting the efficacy and safety of iberdomide and mezigdomide as monotherapy and combined with other systemic therapies for patients with R/R MM, including emerging positive results from the Phase III SUCCESSOR-2 study of mezigdomide combination therapy
• Emerging findings from the Phase III EXCALIBER-RRMM study indicating an improvement in minimal residual disease negativity rates with iberdomide/daratumumab/dexamethasone compared to daratumumab/bortezomib/dexamethasone
• Other ongoing studies evaluating CELMoD-containing therapy for newly diagnosed and R/R MM; potential clinical role of CELMoDs
• Other promising strategies in clinical development for patients with R/R MM

11:40 AM – 12:30 PM — Module 5: Gastroesophageal Cancers

Role of Anti-PD-1/PD-L1- and CLDN18.2-Directed Antibodies in the Management of Gastroesophageal Cancers

• Early data with immune checkpoint inhibitors as neoadjuvant therapy for resectable microsatellite instability-high(MSI-H)/mismatch repair-deficient (dMMR) gastric/gastroesophageal junction (GEJ) adenocarcinoma
• Available efficacy and safety findings from the Phase III MATTERHORN study evaluating durvalumab added to perioperative fluorouracil/leucovorin/oxaliplatin/docetaxel (FLOT) and continued as a single agent versus perioperative FLOT alone for patients with resectable gastric/GEJ cancer
• FDA approval of perioperative durvalumab for resectable localized and locally advanced gastric and GEJ cancers and current clinical role
• Published datasets demonstrating the efficacy and safety of first-line nivolumab-, pembrolizumab- and tislelizumab-containing regimens for advanced gastric, GEJ and esophageal cancer; impact of PD-L1 expression on outcomes
• Narrowing of the FDA-approved indications for anti-PD-1 antibody-containing regimens for previously untreated HER2-negative gastroesophageal cancers
• Key efficacy and safety results with zolbetuximab in combination with chemotherapy as first-line treatment for CLDN18.2-positive advanced gastric/ GEJ adenocarcinoma
• FDA approval and current clinical role of up-front zolbetuximab/chemotherapy for advanced gastric/GEJ adenocarcinoma
• Spectrum, frequency and severity of adverse events associated with zolbetuximab; optimal approaches to prevention and management
• Biological rationale for combining zolbetuximab and anti-PD-1/PD-L1 antibodies
• Recently presented results from Cohort 4 of the Phase II ILUSTRO trial of first-line zolbetuximab with modified FOLFOX6 and nivolumab for CLDN18.2-positive metastatic gastric/GEJ adenocarcinoma
• Mechanism of action of, early efficacy and safety results with and ongoing Phase III CLARITY-Gastric01 study of the CLDN18.2-targeted antibody-drug conjugate sonesitatug vedotin for advanced gastroesophageal cancers

Management of HER2-Positive Gastroesophageal Cancers

• Long-term follow-up with the addition of pembrolizumab to chemotherapy and trastuzumab for previously untreated HER2-positive advanced gastric/GEJ adenocarcinoma; impact of PD-L1 status on outcomes and revised FDA indication
• Current role of pembrolizumab in combination with chemotherapy and trastuzumab for previously untreated HER2-positive advanced gastric/GEJ adenocarcinoma
• Key efficacy and safety findings with trastuzumab deruxtecan (T-DXd) for patients with progressive HER2-positive gastric/GEJ cancer
• Published efficacy and safety data from the Phase III DESTINY-Gastric04 trial comparing T-DXd to ramucirumab/paclitaxel for patients with HER2-positive metastatic gastric cancer or GEJ adenocarcinoma who had previously received trastuzumab-based therapy
• Optimal integration of T-DXd into current management paradigms for advanced HER2-positive gastroesophageal tumors
• Early results (eg, DESTINY-Gastric03) with T-DXd in combination with other systemic therapies for advanced HER2-positive gastroesophageal cancers
• Mechanism of action of the novel HER2-targeted bispecific antibody zanidatamab
• Published findings with zanidatamab/chemotherapy as first-line treatment for advanced HER2-positive gastroesophageal adenocarcinoma
• Published results from the Phase III HERIZON-GEA-01 trial evaluating zanidatamab and chemotherapy with or without tislelizumab as first-line treatment for advanced HER2-positive gastroesophageal adenocarcinoma
• Ongoing Phase III efforts investigating T-DXd (DESTINY-Gastric05, ARTEMIDE-Gastric01) as a component of up-front therapy for advanced HER2-positive gastroesophageal adenocarcinoma

12:30 PM – 1:20 PM — Lunch Break

1:20 PM – 2:10 PM — Module 6: Desmoid Tumors and Soft Tissue Sarcoma

Desmoid Tumors

• Incidence and prognosis of desmoid tumors; threshold for initiating active therapy
• Outcomes associated with local treatment strategies and historical systemic approaches for desmoid tumors, such as tyrosine kinase inhibitors, chemotherapy, hormonal therapy and anti-inflammatory agents
• Scientific rationale for targeting the gamma secretase complex and Notch pathway as a therapeutic approach for desmoid tumors; mechanism of action of nirogacestat and varegacestat
• Major efficacy and safety findings from the Phase III DeFi trial evaluating nirogacestat versus placebo for progressive desmoid tumors
• FDA approval of nirogacestat for patients with progressing desmoid tumors; optimal selection of candidates for this strategy
• Spectrum, frequency, severity and management of adverse events documented with nirogacestat
• Published and emerging findings from the Phase II/III RINGSIDE study of varegacestat for progressing desmoid tumors; potential clinical role
• Other promising agents and strategies under investigation for desmoid tumors

Soft Tissue Sarcoma (STS)

• Heterogeneity of STS; variability in clinical presentation, molecular landscape and prognosis of different histologic subtypes
• Historical management of advanced STS; appropriate selection and sequencing of chemotherapeutic and other approved agents
• Rationale for targeting the mTOR pathway in patients with perivascular epithelioid cell tumor (PEComa); mechanistic similarities and differences between nab-sirolimus and other mTOR inhibitors
• Major efficacy and safety findings with and current clinical role of nab-sirolimus for locally advanced unresectable or metastatic PEComa
• Key efficacy and safety data leading to the recent FDA approval of the T-cell receptor gene therapy afamitresgene autoleucel for patients with pretreated, advanced synovial sarcoma and MAGE-A4 expression; practical considerations for use in clinical practice
• Published results from the pivotal IGNYTE-ESO trial with letetresgene autoleucel for patients with synovial sarcoma or myxoid/round cell liposarcoma who had received 2 or more prior lines of therapy; potential clinical role
• Published research supporting the use of other novel strategies, such as immune checkpoint inhibitors, for unique STS subtypes
• Available findings and ongoing research with other novel agents and strategies for advanced STS

2:10 PM – 3:00 PM — Module 7: Urothelial Bladder Cancer

Role of Immunotherapeutic Strategies in the Management of Nonmetastatic Urothelial Bladder Cancer (UBC); Emerging Utility of Circulating Tumor DNA (ctDNA) Evaluation

• Rationale for the evaluation of anti-PD-1/PD-L1 antibodies in combination with BCG for patients with BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC); potential role in practice
• Available efficacy and safety outcomes from the Phase III CREST and POTOMAC studies evaluating sasanlimab and durvalumab, respectively, in combination with BCG for BCG-naïve high-risk NMIBC
• Long-term findings with pembrolizumab monotherapy for patients with BCG-unresponsive high-risk NMIBC
• Key findings from the Phase III NIAGARA trial evaluating neoadjuvant durvalumab in combination with gemcitabine/cisplatin followed by radical cystectomy and adjuvant durvalumab monotherapy for patients with muscle-invasive bladder cancer (MIBC)
• FDA approval of durvalumab with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after radical cystectomy, for patients with MIBC; current clinical role
• Published results from the Phase III IMvigor011 trial evaluating adjuvant atezolizumab for patients with high-risk MIBC and positive ctDNA test results after cystectomy
• Prognostic and predictive impact of ctDNA status noted in other research studies in nonmetastatic UBC
• Potential clinical utility of ctDNA testing for guiding treatment decision-making, including regarding the use of adjuvant atezolizumab, and monitoring for recurrence

Other Novel Agents and Strategies for Nonmetastatic and Metastatic UBC

• Advantages of intravesical delivery systems in administering systemic therapies to patients with nonmetastatic UBC
• Available findings from the Phase IIb SunRISe-1 study evaluating the gemcitabine intravesical system with cetrelimab, the gemcitabine intravesical system alone or cetrelimab alone for patients with BCG-unresponsive high-risk NMIBC who are ineligible for or decline radical cystectomy; ongoing Phase III studies evaluating the gemcitabine intravesical system
• FDA approval of the gemcitabine intravesical system for BCG-unresponsive NMIBC with carcinoma in situ with and without papillary tumors; selection of appropriate candidates for this strategy and ongoing Phase III studies
• Initial safety and efficacy results with the TAR-210 erdafitinib intravesical delivery system for patients with NMIBC and select FGFR alterations; ongoing Phase III MoonRISe-1 and MoonRISe-3 trials
• Key outcomes from the Phase III KEYNOTE-905/EV-303 and KEYNOTE-B15/EV-304 studies evaluating perioperative enfortumab vedotin/pembrolizumab for cisplatin-ineligible and cisplatin-eligible patients with MIBC, respectively
• Recent FDA approval of perioperative pembrolizumab/enfortumab vedotin for cisplatin-ineligible patients with MIBC; current role in this population and potential utility for patients who are eligible for cisplatin
• Current clinical role of erdafitinib alongside other available therapies for patients with progressive FGFR-altered metastatic UBC (mUBC)
• Outcomes observed with trastuzumab deruxtecan in the cohort of patients with previously treated mUBC in the Phase II DESTINY-PanTumor02 trial; optimal incorporation into mUBC management
• Published findings from the Phase III RC48-C016 study comparing disitamab vedotin in combination with toripalimab to standard chemotherapy as first-line treatment for HER2-expressing mUBC; ongoing research with disitamab vedotin in global populations

3:00 PM – 3:20 PM — Afternoon Break

3:20 PM – 4:10 PM — Module 8: Triple-Negative Breast Cancer

Current and Future Role of TROP2-Directed Antibody-Drug Conjugates (ADCs) in Therapy for Triple-Negative Breast Cancer (TNBC)

• Scientific rationale for investigating TROP2-directed ADCs for TNBC
• Mechanistic similarities and differences among the TROP2 directed ADCs sacituzumab govitecan (SG), datopotamab deruxtecan (Dato-DXd) and sacituzumab tirumotecan; implications for efficacy and tolerability
• Key efficacy and safety data from the Phase III ASCENT-04/KEYNOTE-D19 study evaluating SG in combination with pembrolizumab for patients with previously untreated PD-L1-positive metastatic TNBC (mTNBC)
• Available findings from the Phase III ASCENT-03 trial comparing SG to chemotherapy as first-line treatment for patients with mTNBC not eligible for immunotherapy
• Major data from the Phase III TROPION-Breast02 study evaluating first-line Dato-DXd versus chemotherapy for patients with advanced TNBC for whom immunotherapy was not an option
• Potential role of SG and Dato-DXd as first-line therapy for mTNBC
• Documented efficacy and safety findings with sacituzumab tirumotecan for patients with mTNBC
• Spectrum, incidence and severity of common and unique adverse events with different TROP2 ADCs
• Recommended algorithms for preventing or mitigating toxicities, such as GI toxicities, neutropenia, oral mucositis/stomatitis and ocular events, documented with one or more TROP2 ADCs
• Ongoing Phase III trials evaluating TROP2 ADCs as a component of first-line therapy for mTNBC, such as TROPION-Breast05 and TroFuse-011, or in (neo)adjuvant therapy for localized disease, such as ASCENT-05, ADAPT-TN-III and IV, TROPION-Breast04 and TroFuse-012 and 032
• Long-term data with SG as monotherapy for patients with previously treated mTNBC

Established Treatment Paradigm for Localized and Metastatic TNBC

• Recommended approaches to and optimal timing of biomarker assessment for patients with localized and metastatic TNBC
• Long-term data from the Phase III KEYNOTE-522 trial evaluating neoadjuvant pembrolizumab combined with chemotherapy and continued as a single agent after surgery for high-risk localized TNBC
• Patient selection for and practical application of neoadjuvant and adjuvant pembrolizumab
• Key efficacy and safety findings, including overall survival outcomes, among patients with TNBC in the Phase III OlympiA trial assessing adjuvant olaparib versus placebo for high-risk, BRCA-mutant, HER2-negative breast cancer
• Current clinical role of adjuvant olaparib for patients with TNBC and a germline BRCA1/2 mutation
• Long-term data guiding the use of PARP inhibitors for patients with mTNBC and BRCA or other homologous recombination repair gene mutations
• Current role of rechallenge with anti-PD-1/PD-L1 antibodies or PARP inhibitors for patients with mTNBC who received these agents in the (neo)adjuvant setting
• Incidence of hormone receptor (HR)-negative, HER2-low mTNBC; antitumor activity of trastuzumab deruxtecan (T-DXd) in this setting
• Current role of T-DXd in therapy for HR-negative, HER2-low breast cancer; optimal sequencing in view of other available treatment options
• Mechanisms of resistance to currently used ADCs; role of T-DXd after disease progression on SG or Dato-DXd, and vice versa
• Frequency of brain metastases observed in patients with mTNBC; implications for therapeutic selection
• Early findings with and ongoing investigations of other novel agents and strategies for TNBC

4:10 PM – 5:00 PM — Module 9: HER2-Positive Breast Cancer

Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer

• Key clinical factors affecting the selection of neoadjuvant and adjuvant systemic therapy for patients with HER2-positive localized breast cancer; effect of various therapeutic approaches on outcomes
• Published findings from the Phase III DESTINY-Breast11 study evaluating trastuzumab deruxtecan (T-DXd) as a component of neoadjuvant therapy for patients with high-risk, HER2-positive localized breast cancer
• Key efficacy and safety data from the Phase III DESTINY-Breast05 study of T-DXd versus trastuzumab emtansine (T-DM1) for patients with high-risk, HER2-positive primary breast cancer with residual invasive disease after neoadjuvant therapy
• Potential implications of DESTINY-Breast11 and DESTINY-Breast05 for the management of HER2-positive localized breast cancer
• Long-term findings from the Phase III ExteNET trial and real-world datasets (eg, ELEANOR) evaluating neratinib as extended adjuvant treatment for HER2-positive localized breast cancer
• Optimal integration of postadjuvant neratinib into routine practice; clinical factors guiding its use, such as hormone receptor status and extent of disease
• Dose-escalation and other available approaches to mitigate neratinib-associated gastrointestinal toxicities
• Ongoing clinical research trials evaluating novel HER2-directed approaches for patients with localized HER2-positive breast cancer

Contemporary Management of HER2-Positive Metastatic Breast Cancer (mBC)

• Published efficacy and safety findings from the Phase III DESTINY-Breast09 trial of T-DXd in combination with pertuzumab versus taxane/trastuzumab/pertuzumab as first-line therapy for HER2-positive mBC
• FDA approval of T-DXd in combination with pertuzumab as first-line treatment for HER2-positive mBC; implications for therapeutic sequencing
• Presented data from the Phase III HER2CLIMB-05 study assessing tucatinib in combination with standard first-line maintenance therapy after chemotherapy-based induction for HER2-positive mBC; potential role of this strategy
• Optimal management approaches for HER2-positive, HR-positive mBC
• Incidence of brain metastases in HER2-positive mBC; available data documenting the CNS activity observed with T-DXd and tucatinib-based therapy
• Long-term findings with and optimal integration into the care of patients with progressive HER2-positive mBC of other evidence-based treatment options, such as neratinib/capecitabine, margetuximab/chemotherapy and T-DM1
• Other promising agents and strategies under investigation for advanced HER2-positive breast cancer
• Frequency of HER2 mutations in patients with mBC; published findings with neratinib-based therapy for this population

5:00 PM — Adjourn

Sunday, April 26, 2026

7:00 AM – 8:00 AM — Registration and Breakfast

8:00 AM – 9:40 AM — Module 10: HR-Positive Breast Cancer

Current and Future Management of Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer

• Clinicopathologic factors affecting the risk of recurrence for patients with HR-positive, HER2-negative localized breast cancer; rationale for the investigation of novel strategies (eg, CDK4/6 inhibitors, oral selective estrogen receptor degraders [SERDs]) in the adjuvant setting
• Extended follow-up, including overall survival (OS) outcomes, from the Phase III monarchE trial evaluating the addition of abemaciclib to standard adjuvant hormonal therapy for patients with high-risk, HR-positive, HER2-negative localized breast cancer
• Long-term results with adjuvant ribociclib and endocrine therapy compared to endocrine therapy alone in the Phase III NATALEE trial
• FDA-approved indications and identification of appropriate candidates for adjuvant abemaciclib and ribociclib
• Other relevant studies (eg, the Phase II TRADE trial) attempting to optimize the use of CDK4/6 inhibitors in the adjuvant setting
• Design, eligibility criteria and primary and second endpoints of the Phase III lidERA Breast Cancer study evaluating adjuvant giredestrant versus physician’s choice of adjuvant endocrine monotherapy for patients with HR-positive, HER2-negative localized breast cancer
• Key efficacy and safety outcomes documented with adjuvant giredestrant versus standard adjuvant endocrine therapy in lidERA Breast Cancer
• Potential clinical role of adjuvant giredestrant for HR-positive, HER2-negative localized breast cancer
• Early data with and ongoing Phase III trials of other oral SERDs in the adjuvant setting

Optimizing First-Line Therapy for Patients with HR-Positive Metastatic Breast Cancer (mBC)

• Optimal approach to and timing of assessment of relevant biomarkers in patients with HR-positive mBC; increasing relevance of biomarker evaluation in the up-front setting
• Long-term follow-up from pivotal clinical trials and other relevant research efforts (eg, RIGHT Choice, ABIGAIL, AMBRE) evaluating CDK4/6 inhibitors in HR-positive, HER2-negative mBC
• Optimal selection of a CDK4/6 inhibitor and an endocrine partner for patients with HR-positive, HER2-negative mBC; implications of poor-risk features, patient comorbidities and prior therapeutic exposure
• Key findings, including OS outcomes, from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib and fulvestrant as first-line therapy for patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative mBC
• Current clinical role of inavolisib as a component of up-front therapy for HR-positive, HER2-negative mBC with a PIK3CA mutation
• Design, eligibility criteria and key endpoints of the Phase III SERENA-6 study evaluating a switch from an aromatase inhibitor to camizestrant after detection of an emergent ESR1 mutation during first-line therapy for HR-positive, HER2-negative mBC
• Published findings from SERENA-6; potential role of serial ESR1 testing using circulating tumor DNA and early therapeutic switching for patients found to harbor mutations
• Emerging findings from the Phase III persevERA study evaluating first-line giredestrant in combination with palbociclib for patients with HR-positive, HER2-negative mBC
• Other ongoing Phase III trials evaluating PI3K/AKT/mTOR pathway inhibitors (INAVO123, CAPItello-292, VIKTORIA-2) and oral SERDs (SERENA-4, pionERA) as a component of first-line therapy for patients with HR-positive, HER2-negative mBC; estimated completion dates

Current and Future Role of Oral SERDs for Progressive HR-Positive mBC

• Structural and mechanistic similarities and differences between fulvestrant and approved and investigational oral SERDs; implications for antitumor activity, tolerability and ease of use
• Published efficacy and safety results from the Phase III EMERALD trial and real-world datasets evaluating elacestrant for pretreated HR-positive, HER2-negative mBC
• Updated efficacy results from the Phase III EMBER-3 study evaluating imlunestrant alone or in combination with abemaciclib for HR-positive, HER2-negative mBC pretreated with endocrine therapy with or without a CDK4/6 inhibitor
• FDA approvals of elacestrant and imlunestrant for previously treated HR-positive, HER2-negative, ESR1-mutated mBC; optimal incorporation into management algorithms
• Recently presented data from the Phase III evERA study of giredestrant in combination with everolimus versus standard endocrine therapy in combination with everolimus for pretreated HR-positive, HER2-negative mBC
• Potential clinical role of giredestrant/everolimus for previously treated HR-positive, HER2-positive mBC
• Early-phase data with and ongoing evaluation of other oral SERD-containing combination strategies for progressive HR-positive, HER2-negative mBC
• Comparative side-effect profiles of approved and investigational oral SERDs; appropriate monitoring for and management of adverse events

Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC

• Biological rationale for inhibiting AKT with capivasertib for HR-positive mBC
• Key efficacy and safety data from the Phase IIICAPItello-291 study evaluating capivasertib/fulvestrant for HR-positive, HER2-negative mBC progressing on endocrine therapy with or without a CDK4/6 inhibitor
• FDA approval of capivasertib for patients with PIK3CA/AKT1/PTEN alterations, and current role with regard to other evidence-based options
• Mechanistic similarities and differences between gedatolisib and currently approved therapies targeting the PI3K/AKT/mTOR pathway for HR-positive mBC; implications for antitumor activity
• Design, eligibility criteria and primary and secondary endpoints of the Phase III VIKTORIA-1 trial evaluating gedatolisib in combination with fulvestrant with or without palbociclib for HR-positive, HER2-negative advanced breast cancer in patients whose disease progressed on or after prior CDK4/6 inhibitor therapy and an aromatase inhibitor
• Published findings from the PIK3CA wild-type cohort of VIKTORIA-1; anticipated readout of the PIK3CA-mutated cohort
• Potential role of gedatolisib-containing combination therapy for pretreated HR-positive, HER2-negative mBC that is PIK3CA wild type and PIK3CA mutated
• Incidence, severity and management of adverse events (eg, gastrointestinal toxicities, cutaneous reactions, hyperglycemia) associated with agents targeting the PI3K/AKT/mTOR pathway

9:40 AM – 10:30 AM — Module 11: Colorectal Cancer

Integration of Novel Treatment Strategies and Options into the Management of Colorectal Cancer (CRC)

• Indications and optimal approach to biomarker testing for patients with localized and metastatic colorectal cancer
• Mechanistic rationale for circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) monitoring for the management of CRC
• Available research findings with ctDNA-based MRD monitoring in localized and advanced CRC
• Active studies examining the clinical utility of ctDNA-based MRD testing for guiding treatment decision-making and monitoring for recurrence; potential clinical impact
• Optimal approaches to targeted therapy for patients with BRAF, HER2 and KRAS abnormalities
• Other novel agents and strategies under investigation for CRC

Module 2: Evolving Use of Immune Checkpoint and Kinase Inhibitors for the Management of CRC

• Updated results with dostarlimab as an alternative to surgery for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) locally advanced rectal cancer
• FDA breakthrough therapy designation for dostarlimab for the treatment of locally advanced MSI-H/dMMR rectal cancer
• Ongoing studies (eg, AZUR-1, AZUR-2, AZUR-4) evaluating dostarlimab for resectable colon and rectal tumors
• Early-phase data with neoadjuvant anti-PD-1/PD-L1 antibodies alone or in combination with other immunotherapies for nonmetastatic MSI-H/dMMR colon cancer
• Key findings from the Phase III Alliance A021502/ATOMIC study of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for dMMR Stage III colon cancer
• Potential role of atezolizumab in the adjuvant setting for nonmetastatic MSI-H/dMMR CRC
• Key efficacy and safety findings from the Phase III CheckMate 8HW trial evaluating nivolumab/ipilimumab versus chemotherapy for previously untreated MSI-H/dMMR metastatic CRC (mCRC) and subsequent FDA breakthrough therapy designation
• Identification of appropriate candidates with newly diagnosed MSI-H/dMMR mCRC for dual immune checkpoint inhibition
• Mechanistic similarities and differences between zanzalintinib and other multikinase inhibitors for CRC; rationale for combining zanzalintinib with an anti-PD-1/PD-L1 antibody for microsatellite-stable (MSS)/mismatch repair-proficient (pMMR) mCRC
• Published efficacy and safety data from the Phase III STELLAR-303 trial evaluating zanzalintinib with atezolizumab for pretreated MSS/pMMR mCRC; recent FDA acceptance of a new drug application for zanzalintinib on the basis of these findings
• Planned Phase III STELLAR-316 study of zanzalintinib with or without an immune checkpoint inhibitor for patients with resected Stage II/III CRC who test positive for MRD after the completion of definitive therapy

10:30 AM – 10:50 AM — Morning Break

10:50 AM – 11:40 AM — Module 12: EGFR-Mutated Non-Small Cell Lung Cancer

Current Management of Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)

• Major findings, including overall survival (OS) outcomes, from the Phase III FLAURA2 study evaluating osimertinib combined with chemotherapy versus osimertinib alone as first-line treatment for EGFR-mutated NSCLC
• Extended follow-up, including OS findings, from the Phase III MARIPOSA trial evaluating up-front amivantamab/lazertinib versus osimertinib for patients with metastatic EGFR-mutated NSCLC
• Key data with amivantamab in combination with platinum-based chemotherapy for patients with progressive EGFR-mutated advanced NSCLC
• Published outcomes supporting the recent FDA approval of a subcutaneous formulation of amivantamab
• Available findings from the COMPEL trial evaluating platinum-based chemotherapy with and without osimertinib for patients with EGFR-mutated advanced NSCLC and non-CNS disease progression on first-line osimertinib
• Efficacy and safety of datopotamab deruxtecan for patients with previously treated EGFR-mutated NSCLC in the TROPION-Lung05 and TROPION-Lung01 trials

Nonmetastatic EGFR-Mutated NSCLC, Exon 20 Insertion Mutations and Novel Agents

• Key findings with osimertinib as neoadjuvant, adjuvant or consolidation therapy for patients with nonmetastatic EGFR-mutated NSCLC
• Major efficacy and safety data with amivantamab in combination with platinum-based chemotherapy as first-line treatment for patients with EGFR exon 20-mutant advanced NSCLC
• Emerging findings from the Phase III WU-KONG28 trial comparing sunvozertinib monotherapy to platinum-based chemotherapy for patients with treatment-naïve NSCLC harboring EGFR exon 20 insertion mutations
• Published data supporting the FDA approval of sunvozertinib for patients with metastatic NSCLC with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy
• Clinical activity and safety observed with zipalertinib for patients with pretreated EGFR exon 20-mutant advanced NSCLC, including those who received prior amivantamab
• Outcomes documented with ivonescimab in combination with carboplatin and pemetrexed for patients with EGFR-mutated NSCLC after disease progression on a third-generation tyrosine kinase inhibitor in the Phase III HARMONi trial

11:40 AM – 12:30 PM — Module 13: Prostate Cancer

Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer

• Efficacy and safety data with the oral GnRH antagonist relugolix for advanced prostate cancer
• Major efficacy and safety data, including overall survival outcomes, from the Phase III EMBARK trial evaluating enzalutamide and leuprolide versus enzalutamide or leuprolide alone for patients with nonmetastatic hormone-sensitive prostate cancer (HSPC) and high-risk biochemical recurrence after definitive therapy
• Published data evaluating androgen deprivation therapy (ADT) intensification with apalutamide with or without abiraterone for patients with high-risk, biochemically recurrent nonmetastatic HSPC
• Extended follow-up with abiraterone, enzalutamide and apalutamide in combination with ADT for patients with metastatic HSPC (mHSPC)
• Published data from the Phase III ARANOTE and ARASENS trials evaluating darolutamide/ADT and docetaxel/ADT, respectively, for mHSPC
• Published results from the Phase III CAPItello-281 trial assessing capivasertib with abiraterone/ADT for patients with de novo mHSPC and PTEN deficiency

Other Available and Emerging Therapeutic Approaches

• Published findings with olaparib/abiraterone, niraparib/abiraterone and talazoparib/enzalutamide as first-line therapy for patients with metastatic castration-resistant prostate cancer (CRPC)
• Published data from the Phase III AMPLITUDE trial evaluating the addition of niraparib to abiraterone/prednisone for patients with mHSPC harboring alterations in homologous recombination repair (HRR) genes
• Emerging positive findings from the Phase III TALAPRO-3 study of talazoparib in combination with enzalutamide for patients with HRR-mutated mHSPC
• Mechanistic similarities and differences between saruparib and other PARP inhibitors; ongoing Phase III efforts evaluating saruparib
• Published Phase III datasets with lutetium Lu 177 vipivotide tetraxetan for patients with taxane-naïve and taxane-pretreated PSMA-positive metastatic CRPC
• Recently presented results from the Phase III PSMAddition study evaluating the addition of lutetium Lu 177 vipivotide tetraxetan to hormonal therapy for patients with PSMA-positive mHSPC
• Other novel agents and strategies undergoing evaluation for patients with prostate cancer

12:30 PM – 1:15 PM — Lunch Break

1:15 PM – 2:05 PM — Module 14: Myelofibrosis and Systemic Mastocytosis

Myelofibrosis (MF)

• Appropriate threshold for initiating active therapy for patients with MF; published data supporting early intervention versus observation for individuals with intermediate- and high-risk disease
• Published research database supporting the use of ruxolitinib for patients with intermediate- and high-risk MF; impact of ruxolitinib on symptom control and survival
• Key findings with fedratinib for patients with newly diagnosed MF who are resistant to or intolerant of ruxolitinib
• Key findings with momelotinib for patients with anemia previously treated with a JAK inhibitor in the Phase III MOENTUM trial and for those with JAK inhibitor-naïve disease in the SIMPLIFY-1 trial
• Published clinical research findings supporting the utility of pacritinib for patients with MF and severe thrombocytopenia
• Other promising investigational agents and strategies for patients with MF

Systemic Mastocytosis (SM)

• Rationale for targeting the KIT D816V mutation among patients with SM; mechanistic similarities and differences between avapritinib and next-generation KIT D816V inhibitors (eg, bezuclastinib, elenestinib)
• Published findings from the pivotal Phase II PIONEER trial of avapritinib versus placebo for patients with indolent SM whose symptoms were not adequately controlled with standard therapy
• Outcomes achieved in key studies (eg, EXPLORER, PATHFINDER) evaluating avapritinib for advanced SM
• Published findings from the Phase II SUMMIT study of bezuclastinib for nonadvanced SM
• Available data from Part 1 of the HARBOR study of elenestinib for patients with indolent SM whose symptoms were not adequately controlled with best supportive care
• Ongoing evaluation of elenestinib for patients with indolent SM in Part 2 of the HARBOR study and advanced SM in the AZURE study

2:05 PM – 2:55 PM — Module 15: Targeted Therapies for Non-Small Cell Lung Cancer

Therapeutic Approaches Targeting HER2 and RET

• Major efficacy and safety findings documented with trastuzumab deruxtecan (T-DXd) for patients with non-small cell lung cancer (NSCLC) and HER2 mutations or overexpression
• Published data with zongertinib for treatment-naïve and previously treated HER2-mutated advanced NSCLC
• Key findings documented with sevabertinib for previously treated HER2-mutated advanced NSCLC
• Ongoing evaluation of T-DXd, zongertinib and sevabertinib as first-line treatment for advanced HER2-mutated NSCLC
• Pivotal datasets supporting the FDA approvals of selpercatinib and pralsetinib for patients with RET fusion-driven advanced NSCLC
• Emerging positive findings from the Phase III LIBRETTO-432 trial evaluating selpercatinib as adjuvant therapy for RET fusion-positive NSCLC

Therapeutic Approaches Targeting ALK and ROS1

• Published data with adjuvant alectinib versus platinum-based chemotherapy for patients with resected Stage IB to IIIA NSCLC with an ALK fusion
• Long-term data with novel ALK inhibitors (eg, alectinib, brigatinib, lorlatinib, ensartinib) for ALK-positive metastatic NSCLC
• Key findings documented with the fourth-generation ALK inhibitor neladalkib from the Phase I/II ALKOVE‑1 trial; ongoing Phase III ALKAZAR trial in the first-line setting
• Key data with entrectinib, repotrectinib and taletrectinib for ROS1-positive NSCLC
• Published findings from the Phase I/II ARROS-1 trial of zidesamtinib for pretreated ROS1-positive advanced NSCLC

2:55 PM – 3:45 PM — Module 16: Acute Myeloid Leukemia

Current Management Approaches for FLT3- and IDH-Mutated Acute Myeloid Leukemia (AML)

• Pharmacologic similarities and differences among available FLT3 inhibitors for AML; implications for potency, activity and tolerability
• Principal findings from the Phase III QuANTUM-First study evaluating the addition of quizartinib to chemotherapy and continued as a single agent for patients with newly diagnosed FLT3-ITD-positive AML
• Rationale for the ongoing Phase III QuANTUM-Wild trial evaluating quizartinib in combination with standard intensive induction and consolidation chemotherapy followed by single-agent quizartinib maintenance for FLT3-ITD-negative AML
• Long-term outcomes reported with gilteritinib versus salvage chemotherapy for patients with relapsed/refractory (R/R) AML with a FLT3 mutation
• Published data supporting ivosidenib for newly diagnosed and R/R IDH1-mutant AML
• Major findings with olutasidenib for R/R AML with an IDH1 mutation
• Long-term data supporting enasidenib for R/R IDH2-mutated AML

Current and Future Role of Menin Inhibitors for Patients with AML

• Mechanism of action of menin inhibitors; rationale for their activity in patients with KMT2A-rearranged and NPM1-mutated acute leukemias
• Pharmacologic similarities and differences between approved (revumenib, ziftomenib) and investigational (eg, bleximenib, enzomenib) menin inhibitors
• Published data with revumenib for R/R KMT2A-rearranged acute leukemias and NPM1-mutated AML in the Phase I/II AUGMENT-101 trial
• FDA approvals of revumenib for patients with R/R acute leukemias with a KMT2A translocation and those with R/R AML with NPM1 mutations; appropriate integration into the treatment paradigm for these populations
• Key findings from the Phase I/II KOMET-001 trial evaluating ziftomenib for R/R NPM1-mutated AML
• Recent FDA approval and current role of ziftomenib for R/R NPM1-mutated AML
• Early research findings with and ongoing clinical trials of revumenib and ziftomenib in combination with other AML therapies
• Available data with and ongoing investigations of bleximenib and enzomenib for AML and other acute leukemias
• Spectrum, incidence and severity of side effects, including differentiation syndrome and cardiac toxicity, with menin inhibitors; appropriate monitoring and management protocols

3:45 PM — Adjourn